Phaseline

Targets › RPGR

RPGR (X-linked retinitis pigmentosa GTPase regulator): drug programs, companies and trials

4 programs from 3 companies in 8 trials: 4 Phase 2, 2 Phase 1, 2 Phase 3; Ophthalmology; next expected readout Feb 2027.

Acts as a guanine-nucleotide releasing factor (GEF) for RAB8A and RAB37 by promoting the conversion of inactive RAB-GDP to the active form RAB-GTP. GEF activity towards RAB8A may facilitate ciliary trafficking by modulating ciliary intracellular localization of RAB8A. GEF activity towards RAB37 maintains autophagic homeostasis and retinal function (By similarity). Involved in photoreceptor integrity (By similarity). (UniProt, Q92834)

Open in Phaseline: the race on RPGR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
MeiraGTx Ocular UKAAV5-hRKp.RPGR (botaretigene sparoparvovec, JNJ-74765340)
AAV5-mediated RPGR gene replacement
RPGRPhase 3Retinitis Pigmentosa; X-Linked Retinitis PigmentosaJun 2027
Beacon TherapeuticsrAAV2tYF-GRK1-RPGR
Adeno-associated virus vector expressing human RPGR gene
RPGRPhase 2X-Linked Retinitis PigmentosaFeb 2027
Beacon TherapeuticsLaruparetigene zovaparvovec (AGTC-501)
Adeno-associated virus vector expressing human RPGR gene
RPGRPhase 2X-Linked Retinitis Pigmentosa (XLRP); X-Linked Retinitis PigmentosaDec 2029
4D Molecular Therapeutics4D-125
AAV5-delivered codon-optimized human RPGR transgene
RPGRPhase 1X-Linked Retinitis PigmentosaMay 2029

Conditions

X-Linked Retinitis Pigmentosa (6) Retinitis Pigmentosa (1) X-Linked Retinitis Pigmentosa (XLRP) (1)

Modalities

protein or peptide (2), other (2)

Companies

Beacon Therapeutics (2) MeiraGTx Ocular UK (1) 4D Molecular Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.